We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+3.56%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$4.99B
AUM Growth
-$200M
Cap. Flow
+$955M
Cap. Flow %
19.13%
Top 10 Hldgs %
53.63%
Holding
424
New
126
Increased
60
Reduced
38
Closed
165

Top Buys

Rank Stock Value
1
ANDV
Andeavor
ANDV
+$273M
2
XL
XL Group Ltd.
XL
+$104M
3
ESRX
Express Scripts Holding Company
ESRX
+$97.2M
4
EVHC
Envision Healthcare Holdings Inc
EVHC
+$88.3M
5
CI icon
Cigna
CI
+$69.2M

Top Sells

Rank Stock Value
1
MON
Monsanto Co
MON
+$526M
2
TWX
Time Warner Inc
TWX
+$279M
3
AET
Aetna Inc
AET
+$126M
4
MSCC
Microsemi Corp
MSCC
+$48.9M
5
MHK icon
Mohawk Industries
MHK
+$44.9M

Sector Composition

Rank Sector Weight
1 Technology 20.53%
2 Financials 18.74%
3 Communication Services 6.93%
4 Energy 6.62%
5 Healthcare 6.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PF
376
CALL
DELISTED
Pinnacle Foods, Inc.
PF
– –
-158,300
Closed -$40K
COTV
377
DELISTED
Cotiviti Holdings, Inc.
COTV
– –
-620,000
Closed -$21.4M
PAY
378
DELISTED
Verifone Systems Inc
PAY
– –
-45,745
Closed -$704K
TWX
379
CALL
DELISTED
Time Warner Inc
TWX
– –
-256,500
Closed -$1.18M
TWX
380
DELISTED
Time Warner Inc
TWX
– –
-2,946,303
Closed -$279M
MON
381
CALL
DELISTED
Monsanto Co
MON
– –
-1,069,500
Closed -$2.66M
MON
382
DELISTED
Monsanto Co
MON
– –
-4,505,157
Closed -$526M
MON
383
PUT
DELISTED
Monsanto Co
MON
– –
-650,000
Closed -$32K
BGC
384
DELISTED
General Cable Corporation
BGC
– –
-235,365
Closed -$6.97M
MSCC
385
DELISTED
Microsemi Corp
MSCC
– –
-755,083
Closed -$48.9M
DYN
386
DELISTED
Dynegy, Inc.
DYN
– –
-312,380
Closed -$4.22M
CSRA
387
DELISTED
CSRA Inc.
CSRA
– –
-432,224
Closed -$17.8M
BBL
388
DELISTED
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
– –
-113,531
Closed -$4.51M
GRA
389
DELISTED
W.R. Grace & Co.
GRA
– –
-75,101
Closed -$4.6M
OREX
390
DELISTED
Orexigen Therapeutics, Inc.
OREX
– –
-33,333
Closed –
HK
391
DELISTED
Halcon Resources Corporation
HK
– –
-175,000
Closed -$852K
12 13 14 15
16

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return

UBS O'Connor's Q2 2018 Portfolio in Review

As of Q2 2018, UBS O'Connor held 424 positions worth $4.99B, down 3.9% from $5.19B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

UBS O'Connor deployed $955M of net new capital in Q2 2018, opening 126 new positions and adding to 60 existing holdings. Its largest new stake was Envision Healthcare Holdings Inc: 2,150,000 shares worth $94.6M.

By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 19% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Aetna Inc, an estimated $126M trimmed.

  • UBS O'Connor's largest Q2 2018 buy was Envision Healthcare Holdings Inc: 2,150,000 shares worth $94.6M.
  • UBS O'Connor added most to Andeavor in Q2 2018, an estimated $273M increase.
  • UBS O'Connor's biggest Q2 2018 reduction was Aetna Inc, cutting an estimated $126M.
  • UBS O'Connor fully exited Monsanto Co in Q2 2018, selling an estimated $526M.
  • UBS O'Connor's ten largest holdings make up 54% of its $4.99B portfolio in Q2 2018.
  • UBS O'Connor opened 126 new positions and closed 165 in Q2 2018.
  • UBS O'Connor's portfolio value fell 3.9% quarter-over-quarter to $4.99B.

Based on UBS O'Connor's 13F filing for Q2 2018, filed 14 Aug 2018.